| 
						 
						Not an inside job: How 
						two analysts became SEC whistleblowers 
						
		 
		Send a link to a friend  
 
		
		
		 [April 25, 2017] 
		By Sarah N. Lynch 
		 
		
		WASHINGTON 
		(Reuters) - Four years ago, two analysts who liked to swap notes on 
		numbers they thought looked odd took a fateful step and tipped off U.S. 
		regulators about a company that one of them had watched for months. 
		 
		Orthofix International NV caught one of the analysts' attention in 2012. 
		The Texas-based medical device maker kept hitting ambitious earnings 
		targets and many analysts had "buy" recommendations for the stock. 
		 
		But the analyst thought something was off. Its earnings reports showed 
		it was taking longer than usual for the company to get paid by wholesale 
		customers, invoices were piling up and executives struggled to offer a 
		convincing explanation, saying logistical problems at foreign offices 
		were partly to blame. 
		 
		He spent months tracking quarterly reports and earning calls, and using 
		algorithms to compare Orthofix’s ratios and patterns of sales and 
		inventory turnover with financial data of its peers stored in databases 
		such as Compustat. 
		 
		"I am always on the lookout for something unusual, either just unusually 
		good and under appreciated, or unusually bad," the analyst told Reuters. 
		"This one showed up as a company that looked like it had the potential 
		to be unusually bad." 
		 
		In the spring of 2013, he e-mailed his spreadsheets to a fellow analyst 
		and a friend of more than a decade, with whom he regularly chatted about 
		companies and sectors. 
						
		
		  
						
		"The way we work together is one person makes a suggestion and the other 
		person challenges it," that friend told Reuters. 
		 
		"It is like a war game." 
		 
		Now both men stand to win as much as $2.5 million after Orthofix reached 
		a $8.25 million settlement in January with the Securities and Exchange 
		Commission and several former executives collectively paid $120,000 in 
		penalties to resolve accounting fraud charges. 
		 
		The award might even be bigger, if the SEC also credits the analysts' 
		tip for leading to a second civil settlement concerning foreign corrupt 
		practices charges. 
		 
		The pair declined to be publicly identified, citing concerns that it 
		might jeopardize their current professional relations. 
		 
		Referring to its January settlement with the SEC, Orthofix spokeswoman 
		Denise Landry said the company had self-reported to the regulator and 
		fully cooperated with the government during the investigation. 
		 
		"We are pleased these matters are behind us," she said, declining to 
		comment further. 
		 
		By entering the SEC whistleblower program the duo showed how outsiders 
		with analytical skills and tools and time to spare can accomplish what 
		is typically done by those with inside access to confidential 
		information. 
		 
		The program, established in 2011 under the Dodd-Frank financial reform 
		law, aimed to bolster the SEC's enforcement program by encouraging 
		insiders to report potential fraud. 
		 
		However, since its inception through Sept. 30, 2016, just over a third 
		of the more than $111 million awarded to whistleblowers went to 
		outsiders such as analysts or short-sellers, according to the SEC. 
		 
		"Sometimes outsiders have a particular expertise and they are able to 
		independently piece things together that might not be as obvious to 
		those close to the matter," said Jane Norberg, the head of the SEC's 
		Office of the Whistleblower. 
		 
		"CHANNEL STUFFING" 
		 
		In Orthofix's case, what the two analysts pieced together suggested that 
		Orthofix was goosing its earnings by "channel stuffing." 
		 
		If not disclosed to investors, the practice of flooding distributors 
		with more products than they can use or pay for is illegal. It lets the 
		company smooth earnings by prematurely recognizing revenue, and pushing 
		shortfalls into the future. 
						
		
		  
						
		
            [to top of second column]  | 
            
             
            
			  
            
			The seal of the U.S. Securities and Exchange Commission hangs on the 
			wall at SEC headquarters in Washington, DC, U.S. on June 24, 2011. 
			REUTERS/Jonathan Ernst/File Photo 
              
As the 
SEC settlement later showed, Orthofix was sending various implants from its 
spine division to distributors in Brazil that either lacked regulatory approval, 
or lacked medical instruments needed to use the implants. It then was recording 
products that could not be resold as revenue, and also treating some of the 
price discounts as expenses instead of a revenue reduction, the SEC said. 
 
(Graphic: http://tmsnrt.rs/2pYNwgY) 
 
Even without such details, the analysts felt they had enough to try the SEC's 
program. 
Their 
suspicions turned into near-certainty when in May 2013, Orthofix missed its 
first quarter earnings targets, reporting a 14 percent year-over-year drop in 
net sales that sent its share price tumbling 15 percent. 
 
"That was when the light bulb really goes off," the analyst who first started 
watching the company said. 
 
By then the two had already contacted Jordan Thomas, an attorney at the law firm 
Labaton Sucharow, which specializes in class action litigation and also takes on 
a limited number of whistleblower cases. 
 
The law firm gets paid for its services from a portion of the award, but it does 
not publicly disclose its share. 
 
A TIP AND A FOLLOW-UP 
 
In June 2013, Thomas submitted a tip to the SEC on his clients' behalf, 
promising to follow up with a more detailed submission, records show. To bolster 
their case the analysts kept picking through the Orthofix's financial 
statements, while Labaton's investigators, led by a former FBI agent, hit the 
phones and scouted industry message boards looking for former Orthofix 
employees. 
One 
former employee they found revealed in an interview that in order for them to 
"make their numbers," the company sent large orders to distributors, only to 
have them returned and then reshipped to other customers, according to the 
updated submission Labaton send to the SEC in August. 
  
The update included the analysts' estimates by how much Orthofix would need to 
lower their earnings and sales for 2011 and 2012. Those numbers later turned out 
to be right in line with what the company ultimately restated in 2014 and 2015. 
 
The SEC still does not know the identities of the two analysts, but it will find 
out in May, when Thomas submits a claim on their behalf asking the SEC to 
consider giving them an award for their tip. 
 
The analysts, who live in different cities, said that the day the SEC charged 
Orthofix, they were just too far apart to get together and celebrate, but that 
an award would justify the trip. 
 
"If and when the actual award settlement is disclosed, then we can meet up for 
champagne," one said. 
 
(Reporting by Sarah N. Lynch in Washington; Editing by Tomasz Janowski) 
				 
			[© 2017 Thomson Reuters. All rights 
				reserved.] Copyright 2017 Reuters. All rights reserved. This material may not be published, 
			broadcast, rewritten or redistributed.  |